Evidence map›Paper›PMID 26446786›Full record

ArticleThe Journal of biological chemistry2015

Competitive Inhibition of the Endoplasmic Reticulum Signal Peptidase by Non-cleavable Mutant Preprotein Cargos.

Jingqiu Cui, Wei Chen, Jinhong Sun, Huan Guo, Rachel Madley, Yi Xiong, Xingyi Pan, Hongliang Wang, Andrew W Tai, Michael A Weiss and 2 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Biosafety and health · 2026
    Article
  3. Article
  4. Article
  5. Pathogenic signal peptide variants in the human genome.NAR genomics and bioinformatics · 2023
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. IFN-γ treatment protocol for MHC-IJournal for immunotherapy of cancer · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Jingqiu CuiDepartment of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin 300052, China,; Division of Metabolism, Endocrinology, and Diabetes, University of Michigan Medical School, Ann Arbor, Michigan 48105.
Wei ChenDivision of Metabolism, Endocrinology, and Diabetes, University of Michigan Medical School, Ann Arbor, Michigan 48105,; Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
Jinhong SunDivision of Metabolism, Endocrinology, and Diabetes, University of Michigan Medical School, Ann Arbor, Michigan 48105.
Huan GuoDivision of Metabolism, Endocrinology, and Diabetes, University of Michigan Medical School, Ann Arbor, Michigan 48105.
Rachel MadleyDivision of Metabolism, Endocrinology, and Diabetes, University of Michigan Medical School, Ann Arbor, Michigan 48105.
Yi XiongDivision of Metabolism, Endocrinology, and Diabetes, University of Michigan Medical School, Ann Arbor, Michigan 48105.
Xingyi PanDivision of Metabolism, Endocrinology, and Diabetes, University of Michigan Medical School, Ann Arbor, Michigan 48105.
Hongliang WangDivision of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109.
Andrew W TaiDivision of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109.
Michael A WeissDepartment of Biochemistry, Case Western Reserve University, Cleveland, Ohio 44106. Electronic address: michael.weiss@case.edu.
Peter ArvanDivision of Metabolism, Endocrinology, and Diabetes, University of Michigan Medical School, Ann Arbor, Michigan 48105.
Ming LiuDepartment of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin 300052, China,; Division of Metabolism, Endocrinology, and Diabetes, University of Michigan Medical School, Ann Arbor, Michigan 48105.
University of Michigan–Ann Arbor · USCase Western Reserve University · USTianjin Medical University General Hospital · CN

Funding

PUBLIC HEALTH DEMONSTRATIONP60DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MYERS, MARTIN G · 1985 to 2012
$26.5M
Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
Proinsulin Trafficking for Insulin BiosynthesisR01DK048280 · NIDDK · YESHIVA UNIVERSITY · PI ARVAN, PETER · 1994 to 2024
$10.5M
Non-Standard Protein Design in Molecular Endocrinology: Insulin and GlucagonR01DK040949 · NIDDK · UNIVERSITY OF CHICAGO · PI CHERRINGTON, ALAN D, GEORGIADIS, MILLIE M · 1989 to 2024
$8.4M
How mutations in proinsulin cause diabetes: a protein-misfolding diseaseR01DK069764 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI ARVAN, PETER, KENT, STEPHEN B.H. · 2004 to 2014
$3.5M
Subversion of hepatocyte phosphoinositide metabolism by hepatitis C virusR01DK097374 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TAI, ANDREW W. · 2013 to 2017
$1.7M
Preproinsulin Translocation and Processing at the ER Membrane: a link to DiabetesR01DK088856 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LIU, MING · 2011 to 2015
$1.4M
NIDDK NIH HHS P30 DK020572NIDDK NIH HHS P60 DK020572NIDDK NIH HHS P60-DK20572NIDDK NIH HHS R01 DK040949NIDDK NIH HHS R01 DK048280NIDDK NIH HHS R01 DK069764NIDDK NIH HHS R01-DK069764NIDDK NIH HHS R01 DK088856NIDDK NIH HHS R01-DK088856NIDDK NIH HHS R01 DK097374NIDDK NIH HHS R01-DK097374NIDDK NIH HHS R01-DK48280
6 · The paper itself

Abstract

Upon translocation across the endoplasmic reticulum (ER) membrane, secretory proteins are proteolytically processed to remove their signal peptide by signal peptidase (SPase). This process is critical for subsequent folding, intracellular trafficking, and maturation of secretory proteins. Prokaryotic SPase has been shown to be a promising antibiotic target. In contrast, to date, no eukaryotic SPase inhibitors have been reported. Here we report that introducing a proline immediately following the natural signal peptide cleavage site not only blocks preprotein cleavage but also, in trans, impairs the processing and maturation of co-expressed preproteins in the ER. Specifically, we find that a variant preproinsulin, pPI-F25P, is translocated across the ER membrane, where it binds to the catalytic SPase subunit SEC11A, inhibiting SPase activity in a dose-dependent manner. Similar findings were obtained with an analogous variant of preproparathyroid hormone, demonstrating that inhibition of the SPase does not depend strictly on the sequence or structure of the downstream mature protein. We further show that inhibiting SPase in the ER impairs intracellular processing of viral polypeptides and their subsequent maturation. These observations suggest that eukaryotic SPases (including the human ortholog) are, in principle, suitable therapeutic targets for antiviral drug design.

Indexed as

Endoplasmic ReticulumHEK293 CellsHumansMembrane ProteinsProtein PrecursorsProteolysisSerine EndopeptidasesMembrane ProteinsProtein PrecursorsSerine Endopeptidasestype I signal peptidaseenzyme inhibitormutantprotein processingprotein synthesisprotein traffickingsecretory proteinsignal peptidaseviral polypeptide

Identifiers

PMID26446786
PMCPMC4653672
OpenAlexW2286847415

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.